StockNews.AI
EW
StockNews.AI
26 days

Edwards Lifesciences Reports Second Quarter Results

1. Q2 sales grew 11.9% to $1.53 billion, showing strong performance. 2. TAVR sales increased by 8.9%; adjusted EPS rose to $0.67.

Earnings
+5.54%Current Return
VS
+0.41%S&P 500
$75.807/24 04:23 PM EDTEvent Start
$8007/25 10:38 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The significant sales growth and TAVR performance are likely to enhance investor confidence. Historical trends show that consistent sales growth positively influences stock performance.

How important is it?

The strong earnings report and sales figures are crucial indicators of EW's financial health and market position.

Why Short Term?

Earnings results typically have immediate effects on stock prices; investor sentiment will likely respond quickly.

Related Companies

MDTSYKBSX
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomati.

Related News